Phase 2 Study of Daratumumab in Combination With Thalidomide and Dexamethasone in Relapse and / or Refractory Myeloma
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2018
At a glance
- Drugs Daratumumab (Primary) ; Dexamethasone (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 05 Jun 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
- 05 Jun 2018 Status changed from not yet recruiting to recruiting.
- 10 May 2017 New trial record